retatrutide gip glp-1 glucagon receptor agonist PDB-101: Molecule of the Month: Agonists retatrutide triple hormone receptor agonist

In rare cases, this can increase the risk of regurgitation and aspirationstomach contents going into the lungswhich can lead to pneumonia, prolonged hospital stay, or even intensive care

108 Another retrospective study reported that in a population with T2DM and previously diagnosed MASLD/MASH, GLP-1RA is associated with a decreased incidence of hepatocellular carcinoma (HCC) and a reduced risk of hepatic decompensation events compared with other antidiabetic agents

Cell Physiol Biochem

Meta-analysis data shows retatrutide producing approximately 38% greater weight loss than tirzepatide (16.34 kg versus 11.82 kg)

The starting dose period occupies the first 4 to 8 weeks